Header Logo

Heather Mary Shaw RN

InstitutionUMass Chan Medical School
DepartmentTan Chingfen Graduate School of Nursing
AddressUniversity of Massachusetts Medical School
55 Lake Ave North
Worcester MA 01605
vCardDownload vCard
    Other Positions
    InstitutionTan Chingfen Graduate School of Nursing
    DepartmentTan Chingfen Graduate School of Nursing

    Collapse Biography 
    Collapse education and training
    University of Massachusetts Medical School, Worcester, MA, United StatesBSNNursing

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I, Steven N, Lorigan P, Plummer R, Patel P, Psarelli E, Olsson-Brown A, Shaw H, Leyvraz S, Handley L, Rawcliffe C, Nathan P. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. Eur J Cancer. 2024 Mar 11; 202:114009. PMID: 38547774.
    2. Bj?rk JR, Bolte LA, Maltez Thomas A, Lee KA, Rossi N, Wind TT, Smit LM, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Spector TD, Bataille V, Segata N, Hospers GAP, Weersma RK. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat Med. 2024 Mar; 30(3):785-796. PMID: 38365950.
    3. Awan S, Bharucha P, Steventon L, Simpson H, Ahmad T, Benafif S, Shaw H, Chambers P. Out-of-hours admissions in patients treated with immune checkpoint inhibitors and their primary management with steroids. J Oncol Pharm Pract. 2023 Oct 17; 10781552231207271. PMID: 37847586.
      Citations:    Fields:    
    4. Howlett S, Carter TJ, Shaw HM, Nathan PD. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Ther Adv Med Oncol. 2023; 15:17588359231160140. PMID: 36970111.
    5. Visconti A, Rossi N, Deri? H, Lee KA, Hanic M, Trbojevic-Akmacic I, Thomas AM, Bolte LA, Bj?rk JR, Hooiveld-Noeken JS, Board R, Harland M, Newton-Bishop J, Harries M, Sacco JJ, Lorigan P, Shaw HM, de Vries EGE, Fehrmann RSN, Weersma RK, Spector TD, Nathan P, Hospers GAP, Sasieni P, Bataille V, Lauc G, Falchi M. Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma. BMC Cancer. 2023 Feb 18; 23(1):166. PMID: 36805683.
      Citations: 2     Fields:    Translation:Humans
    6. Rossi N, Lee KA, Bermudez MV, Visconti A, Thomas AM, Bolte LA, Bj?rk JR, de Ruijter LK, Newton-Bishop J, Harland M, Shaw HM, Harries M, Sacco J, Board R, Lorigan P, de Vries EGE, Segata N, Taams L, Papa S, Spector TD, Nathan P, Weersma RK, Hospers GAP, Fehrmann RSN, Bataille V, Falchi M. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma. EBioMedicine. 2022 Sep; 83:104235. PMID: 36007304.
      Citations: 4     Fields:    Translation:Humans
    7. Lee KA, Thomas AM, Bolte LA, Bj?rk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med. 2022 03; 28(3):535-544. PMID: 35228751.
      Citations: 76     Fields:    Translation:Humans
    8. Wong YNS, Sng CCT, Ottaviani D, Patel G, Chowdhury A, Earnshaw I, Sinclair A, Merry E, Wu A, Galazi M, Benafif S, Soosaipillai G, Chopra N, Roylance R, Shaw H, Lee AJX. Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital. Cancers (Basel). 2021 Dec 02; 13(23). PMID: 34885194.
    9. Tan E, Shaw H, Nathan P, Ghosh-Ray S, Ottaviani D. Subacute CNS Demyelination After Treatment With Immune Checkpoint Inhibitors. Neurol Clin Pract. 2021 Dec; 11(6):e949-e951. PMID: 34992993.
    10. Sng CCT, Wong YNS, Wu A, Ottaviani D, Chopra N, Galazi M, Benafif S, Soosaipillai G, Roylance R, Lee AJX, Shaw H. Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience. Front Oncol. 2020; 10:595804. PMID: 33330085.
    11. Lee KA, Shaw H, Bataille V, Nathan P. Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity. J Immunother Cancer. 2020 10; 8(2). PMID: 33020237.
      Citations: 3     Fields:    Translation:Humans
    12. Lee KA, Shaw HM, Bataille V, Nathan P, Spector TD. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications. Eur J Cancer. 2020 10; 138:149-155. PMID: 32889369.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    13. Kristeleit R, Evans J, Molife LR, Tunariu N, Shaw H, Slater S, Haris NRM, Brown NF, Forster MD, Diamantis N, Rulach R, Greystoke A, Asghar U, Rata M, Anderson S, Bachmann F, Hannah A, Kaindl T, Lane HA, Larger PJ, Schmitt-Hoffmann A, Engelhardt M, Tzankov A, Plummer R, Lopez J. Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. Br J Cancer. 2020 10; 123(9):1360-1369. PMID: 32741975.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    14. Mir R, Shaw HM, Nathan PD. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis. Melanoma Res. 2019 02; 29(1):102-106. PMID: 30395075.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    15. Dillon MT, Grove L, Newbold KL, Shaw H, Brown NF, Mendell J, Chen S, Beckman RA, Jennings A, Ricamara M, Greenberg J, Forster M, Harrington KJ. Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. Clin Cancer Res. 2019 01 15; 25(2):487-495. PMID: 30327312.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    16. Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res. 2015 Oct; 25(5):432-42. PMID: 26225580.
      Citations: 24     Fields:    Translation:Humans
    17. Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther. 2013 Sep 03; 6:1197-206. PMID: 24043945.
    18. Shaw HM, Nathan PD. Vemurafenib in melanoma. Expert Rev Anticancer Ther. 2013 May; 13(5):513-22. PMID: 23617343.
      Citations: 6     Fields:    Translation:HumansAnimals
    19. Boyd SC, Mijatov B, Pupo GM, Tran SL, Gowrishankar K, Shaw HM, Goding CR, Scolyer RA, Mann GJ, Kefford RF, Rizos H, Becker TM. Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol. 2013 May; 133(5):1269-77. PMID: 23190890.
      Citations: 23     Fields:    Translation:HumansCells
    20. Bonvin E, Falletta P, Shaw H, Delmas V, Goding CR. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma. Mol Cell Biol. 2012 Nov; 32(22):4674-83. PMID: 22988297.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    21. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010 Sep 01; 28(25):3965-72. PMID: 20679611.
      Citations: 129     Fields:    Translation:HumansCTClinical Trials
    22. Vance KW, Shaw HM, Rodriguez M, Ott S, Goding CR. The retinoblastoma protein modulates Tbx2 functional specificity. Mol Biol Cell. 2010 Aug 01; 21(15):2770-9. PMID: 20534814.
      Citations: 24     Fields:    Translation:HumansCells
    23. Reid AH, Protheroe A, Attard G, Hayward N, Vidal L, Spicer J, Shaw HM, Bone EA, Carter J, Hooftman L, Harris A, De Bono JS. A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin Cancer Res. 2009 Aug 01; 15(15):4978-85. PMID: 19638462.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    24. de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res. 2008 Oct 15; 14(20):6663-73. PMID: 18927309.
      Citations: 46     Fields:    Translation:HumansCellsCTClinical Trials
    25. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007 Oct 01; 13(19):5834-40. PMID: 17908976.
      Citations: 111     Fields:    Translation:HumansCTClinical Trials
    26. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007 Feb; 43(3):481-9. PMID: 17208435.
      Citations: 52     Fields:    Translation:Humans
    Shaw's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (135)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors